Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
How do you choose between darolutamide and abiraterone when adding to docetaxel plus ADT in management of castrate sensitive high burden metastatic prostate cancer?
Related Questions
Do you recommend pharmacological ADT for a patient with hypogonadism with unfavorable or high risk prostate cancer whose testosterone was castrate (<20) without supplementation?
How do you sequence Ra-223 and Lu-177 in patients with mCRPC with predominantly bony disease?
What is the optimal duration of ADT for unfavorable intermediate risk or high risk localized prostate cancer treated with SBRT instead of conventionally fractionated or hypofractionated RT?
Is there any way to safely to treat patients with mCRPC with 177-Lu PSMA who are on hemodialysis?
How would you approach treating a patient with prostate adenocarcinoma with urothelial features?
How do you interpret PSMA/PET with focal prostate activity after XRT currently on ADT with stable PSA?
How can we symptomatically manage dizziness or risk of fall in older patients on enzalutamide ?
Would you extrapolate from EMBARK to use an ARPI other than enzalutamide in high risk biochemically recurrent prostate cancer for a patient with contraindications to enzalutamide?
What is the optimal approach for high risk prostate cancer patients who have been found to have positive nodes after surgery?
How would you treat a patient presenting with de novo metastatic prostate cancer and baseline low testosterone?